Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
NEW YORK, Jan. 04, 2018 -- Centre Lane Partners, LLC recently completed the acquisition of Alternative Biomedical Solutions, LLC (“ABS”).
ABS, headquartered in Carrollton, Texas is an ISO-certified leading supplier of high-performance mass spectrometry, toxicology and chemistry measurement systems. ABS offers a comprehensive line of analyzers, reagents, consumables, laboratory data management systems, and customized service agreements.
“Today’s announcement marks a milestone for our business as a whole and is a testament to ABS’s excellence,” said Simon Bergeron, CEO of ABS. “We have successfully established our brand by offering unparalleled products & services and we will now have an opportunity to expand, delivering the most comprehensive offerings in our industry.”
“Centre Lane has been impressed by the entire ABS organization and is thrilled to partner with the team,” said William James, Principal of Centre Lane. “We believe the Company provides a truly unique service offering and is well-positioned to continue its growth in the toxicology testing market.”
About Centre Lane Partners
Centre Lane Partners is a private investment firm focused on making equity and debt, control and non-control, investments in North American middle market companies. Centre Lane targets companies with revenues between $20 and $500 million that have leading market positions and sustainable competitive advantages in their respective niches. We seek to invest $5 to $250 million per transaction. Industries targeted for investment are broad and diverse.
Investment Opportunities Contact:
Pierre Champion
Vice President of Business Development
[email protected]
+1 (646) 843-0717
